Introduction
Given the complex etiology, type 2 diabetes was recently identified as a priority for the field of precision health (1) . In most people, risk for type 2 diabetes begins with insulin resistance, which is largely undetectable in clinical practice, and progresses to impaired fasting glucose (i.e. fasting blood glucose 100-125 mg dL) before a diagnosis of type 2 diabetes is made. During this prodromal window prior to the diagnosis of type 2 diabetes, harmful conditions (e.g. inflammation) can occur and go largely undetected. (2, 3) Common biomarkers (i.e. fasting blood glucose and hemoglobin A1c) for type 2 diabetes are used for diagnosis and monitoring of the disease but do not identify which individuals are at greatest risk for developing the disease in the prodromal window. Newer biomarkers that provide prognostic information about risk for type 2 diabetes have the potential to improve risk stratification.
MicroRNAs are short (i.e. 18-26 nucleotide) regulatory elements of translation of messenger RNAs to amino acids. Extracellular circulating microRNAs found in serum and plasma are easily measured in blood samples and are potential biomarkers for risk for development of type 2 diabetes, showing changes in expression levels prior to the onset of impaired glucose metabolism. (4, 5) . Because microRNAs capture both underlying genetic risk and responses to behavioral factors (e.g. diet and physical activity) (6,7) they represent several potential biomarker applications. First, as prognostic biomarkers, (8) there is the possibility for improved granularity in detecting glycaemic progression prior to the onset of type 2 diabetes. Second, because microRNAs are associated with individual pathways that singularly and collectively may lead to type 2 diabetes, they are potentially diagnostic biomarkers (8) that will provide greater understanding of which pathways are activated in one individual. Circulating microRNAs are also associated with complications (e.g. endothelial dysfunction) from impaired glucose metabolism that precedes and characterizes type 2 diabetes. (9, 10) Prior studies that evaluated relationships between circulating microRNAs and risk for type 2 diabetes were primarily limited to single measurements of microRNAs. The cross-sectional design of prior studies limits determination of which microRNAs are potentially prognostic biomarkers associated with trajectories of glucose metabolism as opposed to complications from impaired glucose metabolism. (11, 12) The goals of this pilot study were to generate preliminary data about microRNAs as prognostic biomarkers by studying relationships between the trajectories of individual microRNAs and trajectories of fasting blood glucose over time. In addition, associations between risk factors (i.e. weight and fasting blood glucose) for type 2 diabetes following a behavioral intervention trial and circulating microRNAs are presented.
Research design and methods

Study participants
The previously completed Practicing Restorative Yoga vs. Stretching for the Metabolic Syndrome (PRYSMS) study (clinicaltrials.gov identifier NCT01024816) evaluated the effects of restorative yoga versus active stretching on blood glucose in community dwelling adults at risk for type 2 diabetes. (13) Participants in PRYSMS were recruited from the San Francisco and San Diego areas and met the International Diabetes Federation criteria for the metabolic syndrome. (14) Randomization was stratified by sex and race/ethnicity. Participants (n = 171) were randomized to either a restorative yoga or active stretching intervention for 12 months. Both interventions were delivered in a group setting twice weekly for 12 weeks and then weekly for 12 weeks and then monthly for 24 weeks. Participants were asked to practice yoga or stretching at home for at least 30 min three times per week. Fasting blood glucose was measured at baseline and every 3 months for the duration of the 1-year intervention. Plasma was isolated from whole blood and stored at À80°C.
Data from a recently completed randomized controlled trial of a weight loss intervention in Filipino Americans (Fit and Trim Trial) are also presented. The Fit and Trim study was a randomized controlled trial of a physical activity and diet lifestyle intervention for Filipino-Americans. The purpose of the trial was to evaluate an adaptation of the diabetes prevention program (15) that uses mobilepersuasive technologies, cultural tailoring for FilipinoAmericans and a social networking component. Over 3 months, the program's goals were for the participants to lose 5% body weight, increase to and maintain 12,000 steps per day, reduce total fat intake to 25% of daily calories and reduce sugar-sweetened beverages to one every 2 weeks. A total of 62 participants, recruited from the San Francisco Bay Area using community outreach strategies, completed the study. In this study, 3-h oral glucose tolerance tests were performed at baseline. After 3 months, fasting blood glucose and insulin were measured. At both time points, plasma was isolated from whole blood and stored at À80°C. We studied a random subset (n = 8) of participants pre-intervention and 3-months post-intervention.
MicroRNA quantitation
The Firefly Bioworks Multiplex Circulating MicroRNA Assay (Abcam Fireplex, Cambridge, MA, USA) was used to quantify 353 microRNAs from plasma at four time points in a random subset of participants (n = 10) stratified by sex and intervention group from the PRYSMS study. The same assay was used to measure microRNAs from plasma from an additional random subset of participants (n = 8) stratified by sex and intervention group from the Fit and Trim study. This assay performs direct detection of microRNAs from plasma without an isolation step.
Statistical analysis
Descriptive statistics were calculated using means and standard deviations to evaluate demographic and clinical characteristics of participants in the PRYSMS and Fit and Obesity Science & Practice MicroRNAs type 2 diabetes E. Flowers et al. 447 Trim studies and comparisons between groups used Student's t-test (Stata version 13, College Station, TX).
The secondary analysis of the PRYSMS study focused on changes in fasting blood glucose over time. In order to identify patterns of fasting blood glucose in the PRYSMS sample (n = 171) (Figure 1 ), growth mixture modelling (GMM) was performed. GMM is an extension of latent growth curve analysis that extends the estimation of a single growth curve -represented as latent variables: intercept and slope coefficients and variance components for them -to the estimation of a new latent categorical variable that identifies latent growth curves for two or more classes. (16) (17) (18) (19) The model fit for the GMM was assessed statistically by identifying the model with the lowest Bayesian Information Criterion and by testing the 'K' versus 'K-1' class models to determine whether a model with K classes fit the data better than a model with K-1 classes with the Vuong-Lo-MendellRubin likelihood ratio test. (17, 20, 21) Two phenotypic groups (i.e. latent classes) from five glucose measurements over 1 year were identified (Figure 2 , panel A) (Mplus Version 7.4). One GMM group exhibited variable blood glucose and the other group stable blood glucose. The study described here included a subset (n = 10) of participants randomly selected with equal distribution between the GMM groups and across the restorative yoga and active stretching groups. Trajectories of fasting blood glucose for this subset of participants are shown in Figure 2 , panel B.
Expression of individual microRNAs was normalized using the global geometric mean signal of all reliably detected microRNAs in the assay.
Repeated measures analysis of variance was used to determine which microRNAs changed over time between the variable and stable glucose groups in the PRYSMS study (Stata v 14.2, College Station, TX). The false discovery rate method (22) changes over time. Linear models were used to determine whether the trajectories of individual microRNAs were statistically significantly positive or negative or were variable compared with trajectories of fasting blood glucose.
In the Fit and Trim study, paired Student's t-tests were used to compare differences in individual microRNAs before and after the 3-month physical activity and dietary intervention. Pearson's correlation coefficients were calculated to determine associations between baseline levels of individual microRNAs and weight change after 3 months and between changes in individual microRNAs and weight change over 3 months.
Results
The subset of participants from the PRYSMS trial included in this study was equally distributed by sex and had a mean age of 57 ± 4 years. Clinical characteristics at baseline between the two glucose classes are shown in Table 1 . Overall, the variable blood glucose group had a mean increase in fasting blood glucose after 12 months of 2.2 mg dL À1 compared with no change in the stable blood glucose class. Forty-five individual microRNAs were differentially expressed between the GMM groups over 1 year (p < 0.05) ( Table 2 ). Of these, the overall trajectories were positive for one microRNA (i.e. miR-320c) and negative for three microRNAs (i.e. miR-22, miR-372 and miR-339) in the variable glucose group and negative for one microRNA (i.e. miR-423) in the stable glucose group. For the remaining statistically significant microRNAs, the trajectories were variable (i.e. polynomial) across the five time points. Clinical characteristics of the Fit and Trim subset of participants, included in this study, are shown in Table 3 . The mean weight loss after the intervention was 9 ± 4 lb. This represented a 4.8% weight loss following the intervention. In these eight participants, a total of 13 microRNAs were differentially expressed after the weight loss intervention (p < 0.1). Four (i.e. miR-326, miR-24, miR-425 and miR-652) exhibited increased expression after the 3-month intervention. The remaining nine (i.e. miR-106b, miR-140, miR-20b, miR-363, miR-486, miR-532, miR-92a, miR-93 and miR-let7c) exhibited decreased expression after the intervention. Seven (Figure 1 ). Changes in levels of three microRNAs (i.e. miR-146a, miR-151a and miR-23a levels) were very strongly positively correlated (r 2 > 0.8, p < 0.05) with changes in weight over 3 months. An additional nine microRNAs (i.e. miR-181b, miR-181d, miR-21, miR-221, miR-222, miR-223, miR-23, miR-24 and miR-27b) were strongly positively correlated (0.6 < r 2 < 0.8, p < 0.05) with weight change. Baseline levels of eight microRNAs (i.e. miR-143, miR-145, miR-146, miR-191, miR-221, miR23a, miR-29a and miR-584) have a positive association with weight change after 3 months (r 2 > 0.6, p < 0.05).
There were no negative associations between baseline levels of individual microRNAs or change in levels of individual microRNAs with weight change over 3 months.
Conclusion
MicroRNAs are emerging as possible prognostic biomarkers to identify individuals at high risk for type 2 diabetes, and diagnostic biomarkers to characterize individual differences in disease etiology. A limitation of prior studies is the inability to differentiate circulating microRNAs related to risk for type 2 diabetes versus complications of type 2 diabetes. In this study, numerous circulating microRNAs with trajectories that relate to trajectories of fasting blood glucose were identified. Prior observational studies on microRNAs associated with risk for type 2 diabetes have been primarily crosssectional or limited to two measures of fasting blood glucose or related markers. (11, 12, (23) (24) (25) A few prior studies included repeated measures of microRNAs that were pre-post interventions that target pathways associated with risk for type 2 diabetes (e.g. exercise). (6, 7, 24) One of the early contributions in this field identified microRNAs associated with prevalent type 2 diabetes after 10 years in a large cohort study of Europeans. (23) Among the microRNAs identified was miR-126, which is now well established to be an endothelial-related microRNA (26) and possibly related to complications from type 2 diabetes as opposed to mechanisms underlying development of the primary disease (9, 10, 27) . There are potentially useful biomarker applications for microRNAs related to complications, but these are discrete from applications for microRNAs associated with prodromal identification of risk for type 2 diabetes.
This pilot study provided preliminary evidence for 45 potential prognostic microRNA biomarkers with trajectories over 1 year that associate with trajectories of fasting blood glucose. Among these are numerous microRNAs that were previously identified in our own and other prior studies. For example, miR-106b, miR-17, miR-20a and miR-93 are related to a measure of insulin resistance, (28) miR-214, miR-22 and miR-320a are related to insulin resistance and responses to thiazolidenidones (4) and miR-15a, miR-320a and miR-423 are related to glycaemic impairment and progression (5) . The latter two, miR-320a and miR-423, have also been reported in other studies with related mechanisms. (29, 30) A future potential application of microRNAs is as predictive biomarkers (8) to optimize risk reduction interventions. Preliminary work from our group identifies microRNAs that are also associated with behavioral interventions like weight loss in response to a physical activity and diet intervention (e.g. Fit and Trim trial presented as confirmatory data). Taken together, these are promising preliminary data to show that microRNAs are antecedent markers for risk for type 2 diabetes before the development of impaired glucose metabolism and type 2 diabetes (i.e. prognostic and diagnostic biomarkers) and microRNAs may be useful for predicting responses to interventions (i.e. predictive biomarkers). A summary of preliminary data shows some microRNAs show overlap as prognostic and diagnostic biomarkers for risk for type 2 diabetes and predictive biomarkers for responses to interventions, while others are unique (Figure 1) . This study provided preliminary data from a hypothesis generating pilot study. Future studies are needed in three key areas. The first is to validate prognostic biomarker applications of microRNAs in larger samples and to investigate whether clusters of related microRNAs might enhance risk prediction. Second is to further investigate microRNAs as diagnostic biomarkers by identification of mechanistic targets of microRNAs so that underlying pathways can be identified. This will facilitate improved risk stratification and targeted treatments. Third is to expand on preliminary research on microRNAs as predictive biomarkers that predict responses to risk reduction interventions in order to optimize treatment strategies for individuals. This preliminary study has limitations, including a small sample size and moderate differences in fasting blood glucose between groups. Despite these limitations, a large number of microRNAs that were significantly associated with trajectories of fasting blood glucose after adjusting for multiple comparisons were identified. These findings support the need for future studies in larger samples sizes with greater power to model clusters of microRNAs. MicroRNAs may become useful prognostic, diagnostic and predictive biomarkers for prevention and treatment of type 2 diabetes.
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